All Articles

Orchestra BioMed is restructuring partnerships and accelerating clinical trials for its innovative bioelectronic hypertension treatment and sirolimus-eluting coronary intervention device, poised to disrupt established markets.

Biotech firm Terns Pharma is pivoting to focus solely on its lead oncology candidate, TERN-701, a novel CML treatment, after discontinuing development of its metabolic disease programs. Early data signals potential for a best-in-class therapy.

Annexon Biosciences is poised for potentially transformative milestones across its neuroinflammatory disease programs – GBS, GA, and CAD – with key regulatory filings and clinical data readouts expected over the next two years.

American Public Education, Inc. anticipates significant EBITDA growth, fueled by strategic focus and robust nursing/veteran programs. Challenges remain in a sector facing increased regulation and competition.

Insurtech firm Management Data Inc. (MDI) expands into the construction industry with Control360, a platform designed to streamline complex financial litigation in construction defect claims, addressing a significant industry pain point.

Mereo BioPharma is making strides in rare bone disease treatment with its lead candidate, setrusumab, and a new partnership focused on autosomal dominant osteopetrosis. A crucial data readout is anticipated in 2026.

Cybersecurity firm Tenable solidifies its position as a leader in the rapidly growing exposure management space, earning top marks from Gartner and reporting strong financial results driven by its innovative platform.

Data analytics firm Health Catalyst strengthens its commitment to patient privacy and security by earning HITRUST certification across key platforms, setting a new standard in healthcare data protection.

Online cruise booking platform Cruisebound is shaking up the travel industry with its mobile-first experience and transparent pricing. Fresh funding fuels expansion and innovation in a recovering market.

Stereotaxis’ GenesisX system promises to overcome longstanding hurdles to robotic surgery adoption – complex installation and high costs. Can this new approach truly democratize access to precision surgical technology?

A legal battle in Louisiana over prison conditions is drawing national attention, with advocates hoping a Supreme Court decision could set a precedent for improved inmate welfare and rights across the US.

A novel approach to hypertension treatment—targeting aldosterone—shows promise with Mineralys Therapeutics’ lorundrostat, potentially offering a lifeline for millions with resistant hypertension and related conditions.

Profound Medical has reclaimed Canadian distribution rights for its innovative prostate treatment system, TULSA-PRO, signaling confidence in the technology and a strategic move to capitalize on growing demand. The move is expected to enhance access to this minimally invasive treatment.

BYNordic Acquisition Corp. continues its hunt for a Northern European tech target, extending its deadline as the SPAC market evolves. Is this a sign of struggle or strategic patience?

Late-stage trial data suggests Capricor Therapeutics' Deramiocel could address a critical unmet need in Duchenne muscular dystrophy – heart failure. But funding and market access remain key challenges.

Mills Wealth Advisors hosts a free webinar addressing key changes to retirement planning, including updated IRS limits and the impact of the SECURE 2.0 Act. Experts offer insights into navigating the evolving financial landscape.

Clinical-stage biotech Perspective Therapeutics reported a Q3 loss as it invests heavily in radiopharmaceutical research, but maintains a healthy cash position and promising data for hematologic malignancy treatments.

Kaltura’s acquisition of eSelf.ai aims to revolutionize video engagement with lifelike, interactive avatars. But can the company overcome recent financial headwinds to capitalize on this tech?

Oculis Biotech, a clinical-stage biopharmaceutical company, has raised nearly $300 million to accelerate development of innovative therapies for debilitating eye diseases, including optic neuritis and dry eye disease.

Novartis’ acquisition of Avidity Biosciences signals a new era in RNA therapeutics, with a focus on delivering targeted therapies for muscular dystrophies and other genetic diseases. The deal includes a planned spin-off for cardio programs.